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SUMMARY
Objective: To report and review the management of a rare primary stromal sarcoma of the ovary.
Case Report: We report a rare type of ovarian malignancy that occurred in a 60-year-old female. She visited
our department due to lower abdominal discomfort. Ultrasound and abdominal computed tomography showed
a heterogeneous mass over the left adnexa without ascites or lymphadenopathy. During surgery, we found
an irregular ovarian tumor arising from the left adnexa with severe adhesion at the cul-de-sac. Frozen sections
indicated a malignancy, so debulking surgery was performed. The final histopathologic findings showed a low-
grade stromal sarcoma of the left ovary with omental and uterine metastasis. Adjuvant chemotherapy with
a combination of 70 mg/m2 epirubicin, 50 mg/m2 cisplatin, and 6 g ifosfamide was given. Unfortunately, lymph
node metastasis and tumor recurrence were noted at the end of the third course of chemotherapy.
Conclusions: The prognosis for sarcoma is poor and these tumors are always radio-resistant. Adjuvant
chemotherapy with doxorubicin and other agents may provide some response. Unfortunately, we found multiple
intra-abdominal metastases in the patient. The disease course was 10 months. [Taiwanese J Obstet Gynecol 2004;
43(2):110–112]
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Introduction
Primary ovarian sarcomas are extremely rare and usually
behave very aggressively. Treatment includes surgery,
adjuvant radiotherapy and chemotherapy, but no gold
standard has been established due to the limited num-
ber of cases. Debulking surgery is the mainstay of treat-
ment [1]. Here, we report a case of primary ovarian sar-
coma treated with debulking surgery followed by ad-
juvant chemotherapy.
Case Report
A 60-year-old female visited our department because
of intermittent lower abdominal pain in the past few
months. Her history showed that she was well until the
most recent few months. She suffered from intermittent
left lower quadrant pain and was treated in a local
medical department with no success. Ultrasound (Figure
1) and abdominal computed tomography (Figure 2)
showed a complex mass about 12 cm in diameter at
the left adnexa without ascites or lymphadenopathy.
Laboratory data and tumor markers were all within
normal ranges. During surgery, in February 2003, we
found a complex mass from the left adnexa with severe
adhesion at the cul-de-sac. Frozen sections from this
mass showed it to be a malignancy of unknown cell
type. We performed debulking surgery, including a
hysterectomy, bilateral salpingo-oophorectomy, omen-
tectomy, and lymph node sampling. Two drainage tubes
were inserted into the retroperitoneum. The final
111Taiwanese J Obstet Gynecol • June 2004 • Vol 43 • No 2
Ovarian Stromal Sarcoma
histopathologic findings showed a low-grade stromal
sarcoma of the left ovary with omental and uterine
metastases. Immunochemical staining was used for
differential diagnosis of this rare malignant tumor,
including desmin (–), smooth muscle antibody (SMA)
(–), cytokeratin antibody (AE1/AE3) (+), S100 (+), and
vimentin (+). Differential immunochemical staining
results are shown in Figures 3 to 5.
Adjuvant chemotherapy with a combination of
70 mg/m2 epirubicin, 50 mg/m2 cisplatin, and 6 g ifosfa-
mide was arranged 2 weeks after surgery. Unfortunate-
ly, the patient suffered from lower abdominal discom-
fort and was found, by computed tomography in June
2003, to have lymph node metastases and a recurrent
tumor of about 5 cm (at the left obturator fossa) at the
end of the third course of chemotherapy. After discus-
sing the poor outcome of tumor recurrence with the pa-
tient and her family, we changed the regimen to carbo-
platin (AUC5), 100 mg/m2/day etoposide (for 3 days),
and 1 mg/m2 vincristine. The size of the metastasis re-
mained the same after the second course of this second-
line adjuvant chemotherapy.
Due to toxicities and chemo-resistance, we used ex-
ternal radiation after the sixth course of chemotherapy,
but with no success. Unfortunately, we found virulent
progression with multiple intra-abdominal metastases
and obstructive nephropathy in November 2003. At the
time of writing, the patient was in a cachexic state and
receiving home care.
Discussion
Primary ovarian sarcomas are extremely rare and usual-
ly behave aggressively. They account for only a small
percentage (about 1%) of non-epithelial ovarian can-
cers. They are grouped as uncommon ovarian cancers.
To date, only approximately 100 cases have been re-
ported. Most lesions are heterologous, and more than
80% of cases occur in postmenopausal women. They are
biologically aggressive and most patients have evidence
of metastasis.
A report of five cases of primary ovarian sarcoma
between 1987 and 1996 divided tumors into several
subgroups: malignant müllerian-mixed mesodermal
tumor, endometrioid stromal sarcoma (ESS), rhabdo-
myosarcoma, and leiomyosarcoma. All of these have a
poor prognosis, especially in the presence of extra-
ovarian disease [1]. From a histopathologic point of
view, immunochemical staining with, for example,
desmin, SMA, AE1/AE3, S100, and vimentin can be
used in the differential diagnosis. S100 and vimentin
always stain positively in stromal tumors.
Uterine sarcomas are rare, characterized by rapid
clinical progression and poor prognosis, and their
management has presented a challenge. The 5-year
survival rate was 32% overall, 63% for ESS, 30% for
mixed mesodermal sarcomas, and 18% for leiomyo-
Figure 1. Ultrasound showing an irregular solid mass about
12 cm from the left adnexa.
Figure 2. Computed tomography scan showing a hyper-
enhanced 10 × 4 cm irregular soft-tissue mass at the left adnexa.
Figure 3. Staining of frozen sections with AE1/3 (original
magnification, × 200).
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Figure 4. Staining of frozen sections with hematoxylin and
eosin as a control (original magnification, × 400).
Figure 5. Staining of frozen sections with vimentin (original
magnification, × 200).
sarcomas. Only the difference in the 5-year survival
rate between ESS and leiomyosarcomas was statisti-
cally significant. Uterine sarcomas are aggressive tumors
with a poor prognosis. The recommended treatment is
surgery, followed by adjuvant pelvic radiotherapy and/
or systemic chemotherapy [2]. Most cases underwent
total abdominal hysterectomy and bilateral salpingo-
oophorectomy only. The addition of pelvic lymph node
sampling was offered to high-risk patients. In addition,
adjuvant therapy with radiation, chemotherapy, or
combined chemoradiation was also given [3]. The most
effective adjuvant chemotherapy for uterine sarcomas
includes doxorubicin (adriamycin), ifosfamide, and
cisplatin [4].
The mainstay of treatment is debulking surgery,
consisting of total abdominal hysterectomy, bilateral
salpingo-oophorectomy, and extirpation of the tumor
masses. The benefit of postoperative adjuvant chemo-
therapy and/or radiotherapy has not yet been esta-
blished [1]. However, platinum-based combination ad-
juvant chemotherapy is always suggested [5,6].
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